A number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.
A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.
The Prospective Registry Of Multi-Plex Testing (PROMPT) - a new online, volunteer registry for individuals who have been tested for inherited mutations in cancer-causing genes - will provide data vital to improving our understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.
The Hartford HealthCare Cancer Institute has been formally certified as the charter member of the Memorial Sloan Kettering Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for cancer patients in community healthcare settings.
MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.
Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly.
Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals.